The US FDA has given a green light to a new influenza treatment from Shionogi and Roche that has the first new mechanism of action in more than two decades.
Janssen has struck a deal with Arrowhead Pharmaceuticals to develop an RNA interference drug to treat hepatitis B viral infection, worth up to $3.7 billion.
Baloxavir marboxil, a flu drug seen by Roche as a successor to Tamiflu, significantly sped time to relief for patients highly vulnerable to serious complications.
GlaxoSmithKline’s experimental TB vaccine has shown that it could help prevent the disease, but further research is needed to identify patients with the strongest response.